{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:54:39Z","timestamp":1761630879811,"version":"3.37.3"},"reference-count":44,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT BACKGROUND: The introduction of anti-TNF agents represented a landmark in the management of both Crohn\u2019s disease (CD) and ulcerative colitis (UC), with improved efficacy and safety when compared with conventional treatment. However, significant challenges still exist in Latin America to facilitate the access of biological agents for physicians and patients. OBJECTIVE: The aim of this review was to summarize current evidence on penetration of biological agents for CD and UC in Latin America. METHODS: Data are derived from a previous complete systematic review that explored different characteristics of inflammatory bowel diseases (IBD) in Latin America. The studies fully included in this previous systematic review which contained detailed descriptions of the percentage of use of biological agents in different cohorts throughout Latin American and Caribbean countries were included, and descriptive findings were compiled, describing CD and UC penetration of these drugs in different patient cohorts from different countries. RESULTS: From the 61 studies included in the original systematic review, only 19 included data of the percentage of patients treated with biological agents. Anti-TNF use in CD varied from 1.51% in Mexico up to 46.9% in Colombia, with most of the studies describing anti-TNF use in approximately 20%-40% of CD patients. On the other side, the frequency of the use of biologics was clearly lower in UC, varying from 0% in 2009 to up 16.2% in 2018, according to two different Mexican studies. Only two studies described the penetration of anti-TNF agents in IBD overall: 13.4% in a Colombian and 37.93% in a Brazilian study. No studies described percentage of use of new biologic agents (vedolizumab and ustekinumab). CONCLUSION: Penetration of anti-TNF agents in Latin America is comparable to the rest of the world in CD, but lower in UC. With the increase in the incidence and prevalence of IBD, specific strategies to increase access to anti-TNF agents in UC and new biological agents overall are warranted.<\/jats:p>","DOI":"10.1590\/s0004-2803.201900000-59","type":"journal-article","created":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T04:27:40Z","timestamp":1569731260000},"page":"318-322","source":"Crossref","is-referenced-by-count":17,"title":["BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES"],"prefix":"10.1590","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-7402","authenticated-orcid":false,"given":"Abel Botelho","family":"QUARESMA","sequence":"first","affiliation":[{"name":"Universidade do Oeste de Santa Catarina, Brazil; Universidade Cat\u00f3lica do Paran\u00e1, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0916-4138","authenticated-orcid":false,"given":"Claudio Saddy Rodrigues","family":"COY","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7584-7351","authenticated-orcid":false,"given":"Aderson Omar Mour\u00e3o Cintra","family":"DAMI\u00c3O","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G","family":"KAPLAN","sequence":"additional","affiliation":[{"name":"University of Calgary, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2053-5315","authenticated-orcid":false,"given":"Paulo Gustavo","family":"KOTZE","sequence":"additional","affiliation":[{"name":"Universidade Cat\u00f3lica do Paran\u00e1, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"ref1","first-page":"2769","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng SC","year":"2018","journal-title":"Lancet"},{"key":"ref2","article-title":"The progression of inflammatory bowel disease throughout Latin America: a systematic review","author":"Kotze PG","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer SB","year":"2002","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn\u2019s Disease: The CHARM Trial","volume":"132","author":"Colombel JF","year":"2007","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts P","year":"2005","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/apt.12145","article-title":"One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2","volume":"37","author":"Sandborn WJ","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"Feagan BG","year":"2013","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"13","author":"Sandborn WJ","year":"2013","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan BG","year":"2016","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens G","year":"2008","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): A cluster randomised controlled trial","volume":"386","author":"Khanna R","year":"2015","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel J-F","year":"2018","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S2237-93632011000300002","article-title":"Adalimumab in the induction of Crohn\u2019s disease remission: results of a Brazilian multicenter case series","volume":"31","author":"Kotze PG","year":"2011","journal-title":"J Coloproctology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1590\/S0004-28032014000100009","article-title":"Adalimumab for maintenance therapy for one year in Crohn\u2019s disease: results of a Latin American single-center observational study","volume":"51","author":"Kotze PG","year":"2014","journal-title":"Arq Gastroenterol"},{"issue":"321","key":"ref16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1590\/s0004-2803.201700000-51","article-title":"Adalimumab for ulcerative colitis: Results os a Brazilian multicenter observational study","volume":"54","author":"Zacharias P","year":"2017","journal-title":"Arq Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1590\/0100-69912015002006","article-title":"Montreal classification of patient operated for Crohn\u2019s disease and identification of surgical recurrence predictors","volume":"42","author":"Bechara CS","year":"2015","journal-title":"Rev Col Bras Cir"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s10620-017-4685-9","article-title":"Evolution of Clinical Behavior in Crohn\u2019s Disease: Factors Associated with Complicated Disease and Surgery","volume":"62","author":"Barros KSC","year":"2017","journal-title":"Dig Dis Sci"},{"key":"ref19","first-page":"182","article-title":"Descripci\u00f3n epidemiol\u00f3gica y tratamiento de los pacientes con enfermedad de Crohn","volume":"55","author":"Rodr\u00edguez-Castro KI","year":"2013","journal-title":"Acta M\u00e9d Costarric"},{"key":"ref20","first-page":"253","article-title":"Caracterizaci\u00f3n de pacientes con enfermedad de Crohn atendidos en el Instituto de Gastroenterolog\u00eda de Cuba - Characterization of patients with Crohn\u2019s disease cared for at the Institute of Gastroenterology of Cuba","volume":"33","author":"Hano Garc\u00eda OM","year":"2014","journal-title":"Rev Cuba Investig Biom\u00e9dicas"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/359130","article-title":"The Demographic and Clinical Characteristics of Ulcerative Colitis in a Northeast Brazilian Population","volume":"2015","author":"Silva BC","year":"2015","journal-title":"Biomed Res Int"},{"key":"ref22","first-page":"224","article-title":"Comportamiento cl\u00ednico de la colitis ulcerosa cr\u00f3nica inespec\u00edfica en pacientes del CMn 20 de Noviembre, ISSSte, y comparaci\u00f3n con la bibliograf\u00eda Americana","volume":"27","author":"De La Cruz-Guill\u00e9n AA","year":"2011","journal-title":"Med Interna Mex"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jcol.2017.06.004","article-title":"Epidemiological profile and clinical characteristics of patients with intestinal inflammatory disease","volume":"37","author":"Arantes JAV","year":"2017","journal-title":"J Coloproctology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12876-018-0822-y","article-title":"The prevalence and phenotype in Brazilian patients with inflammatory bowel disease","volume":"18","author":"Lima Martins A","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcol.2017.06.009","article-title":"Quality of life of patients with inflammatory bowel disease","volume":"37","author":"Vivan TK","year":"2017","journal-title":"J Coloproctology"},{"key":"ref26","first-page":"1","article-title":"Bone mineral density and inflammatory bowel disease severity","volume":"50","author":"Lima CA","year":"2017","journal-title":"Brazilian J Med Biol Res"},{"key":"ref27","first-page":"200","article-title":"Outpatients profile with inflammatory bowel disease","volume":"24","author":"K Kleinubing J\u00fanior H","year":"2011","journal-title":"Arq Bras Cir Dig"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.3748\/wjg.v22.i22.5267","article-title":"Inflammatory bowel disease: A descriptive study of 716 local Chilean patients","volume":"22","author":"Simian D","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref29","first-page":"240","article-title":"Phenotypes and natural history of Inflammatory Bowel Disease (IBD) in a referral population in Medell\u00edn, Colombia","volume":"25","author":"Ba\u00f1os FJ","year":"2010","journal-title":"Rev Colomb Gastroenterol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1155\/2015\/473726","article-title":"Mild clinical behaviour of Crohn disease in elderly patients in a Latin American country: A case-control study","volume":"29","author":"Yamamoto-Furusho JK","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MCG.0b013e31817a76b4","article-title":"Clinical epidemiology of ulcerative colitis in Mexico: A single hospital-based study in a 20-year period (1987-2006)","volume":"43","author":"Yamamoto-Furusho JK","year":"2009","journal-title":"J Clin Gastroenterol"},{"year":"2018","author":"Yamamoto-Furusho J Sarmiento A","key":"ref32"},{"key":"ref33","first-page":"209","article-title":"Caracteristicas epidemiologicas y clinicas de la enfermedad inflamatoria intestinal en un hospital de referencia de Lima-Peru","volume":"36","author":"Mendez JP","year":"2016","journal-title":"Rev Gastroenterol Peru"},{"key":"ref34","first-page":"3","article-title":"Medication profiles Puerto Rico IBD","volume":"30","author":"Melendez J","year":"2011","journal-title":"P R Health Sci J"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1093\/ecco-jcc\/jjx180.815","article-title":"P688 Demographic, clinical, and therapeutic characteristics of a cohort of 238 patients with ulcerative colitis from two medical centres from Uruguay","volume":"12","author":"Luciano MJ","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: Practical insights","volume":"2","author":"Danese S","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00535-016-1283-0","article-title":"Emerging biologics in inflammatory bowel disease","volume":"52","author":"Chan HC hey","year":"2017","journal-title":"J Gastroenterol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management","volume":"11","author":"Harbord M","year":"2017","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: Diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n F","year":"2017","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/19420862.2018.1484977","article-title":"Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America","volume":"10","author":"Scheinberg M","year":"2018","journal-title":"mAbs"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1590\/s0004-2803.201900000-58","article-title":"Vedolizumab in the management of inflammatory bowel diseases: a Brazilian observational multicentric study","volume":"56","author":"Perin RL","year":"2019","journal-title":"Arq Gastroenterol"},{"key":"ref42","first-page":"1153","article-title":"Vedolizumabe na indu\u00e7\u00e3o da remiss\u00e3o na Retocolite Ulcerativa: Um estudo piloto observacional e multic\u00eantrico","volume":"28","author":"Flores C","year":"2018","journal-title":"Arq Bras Cir Dig Express"},{"year":"2019","author":"Parra Izquierdo V","key":"ref43"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/ecco-jcc\/jjy222.584","article-title":"P460 Efficacy of ustekinumab in patients with anti-TNF refractory Crohn\u2019s disease: data from a real-world study in Brazil","volume":"13","author":"Parra RS","year":"2019","journal-title":"J Crohn\u2019s Colitis"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v56n3\/1678-4219-ag-56-03-318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T07:54:43Z","timestamp":1664524483000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032019000300318&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["S0004-28032019000300318"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.201900000-59","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}